复方延胡索颗粒的制备、质控与初步戒毒作用的研究

目的：研究复方延胡索颗粒的制备、质量控制方法、观察该制剂对吗啡依赖鼠的治疗作用。方法：选用黄芪、延胡索、甘草、远志、酸枣仁、石菖蒲、芸香等七种中药组方制备复方延胡索颗粒,以有效部位部性物碱及有效成分四氢帕马丁的含量作为制备方法的筛选指标及复方延胡索颗粒制的质控指标。总生物碱的含量用非水电位滴定法测定,四氢帕马丁的含量以单波长反射锯齿式薄层扫描外标两点法测定,以该中药制剂治疗吗啡依赖性大鼠自然戒断模型体质量变化百分率作为初步戒毒作用的观察指标。结果：四氢帕马丁在1－6μg范围内线性关系良好（r=0.9992)其仪器精密度、同板精密度良好（RSD＜3．0％）,且在显色后0．5－6h内结果稳定,制剂的加样回收率约为975,复方延胡索颗粒中剂量组（0．6g/kg)和高剂量组（1．2g/kg)对吗啡依赖鼠的体质量下降可产生显治疗作用（P＜0．05,P＜0．01）。结论：本制剂一定剂量可有效控制吗啡身体依赖性大鼠戒断后的体质量下降,对吸毒可能有促进康复的作用。     

高效液相色谱法测定红细胞内α-生育酚

目的：寻找一种测定红细胞内α-生育酚含量的较好方法。方法：将含有生育酚的肝素抗凝血离心后吸出血浆,剩余的红细胞用生理盐水洗涤后用氢氧化钾皂化,并加入联苯三酚以防止α-生育酚被氧化。再用正已烷提取红细胞内的α-生育酚,并进行高效液相层析。结果：α-生育酚浓度为0．927～9．267 μmol／L,线性关系良好,最低检测限为0．323μmol／L,变异系数1．3％,回收率100．2％。结论：该方法简单可靠,重复性好,并可从细胞水平上了解机体的抗脂质过氧化作用。     

双氯酚酸钾片人体生物等效性研究

目的评价双氯酚酸钾实验制剂和参比制剂的生物等效性。方法8名健康男性志愿者交叉单剂量口服双氯酚酸钾实验制剂或参比制剂50mg,采用反相高效液相色谱法测定经时过程血药浓度,血药浓度时间数据用3p97药代动力学实用程序拟合,计算其药代动力学参数。结果实验制剂和参比制剂主要药代动力学参数Ka分别为(3．042±1．356)h     

煤快速加氢热解焦油组成的分析

采用溶剂萃取－化学处理－柱层析相结合的预处理分离程序、色－质联用和色－红联用结合色谱保留值的定性方法,分析研究了内蒙东胜煤快速加氢热解焦油的化学成分和结构,推测鉴定出２００多种化合物,并对具有代表性的１９种多环芳烃进行了定量分析,讨论了快速加氢热解焦油化学成分的结构特征。     

柱切换HPLC法测定腹水中左旋氧氟沙星的含量

目的：应用柱切换ＨＰＬＣ技术直接测定腹水中左旋氧氟沙得含量。方法：采用磷酸二氢钾缓冲溶液（ＰＨ２．２）－０．０５ｍｏｌ／Ｌ四丁溴化化铵（１００：４）为预处理流动相,经μＢｏｎｄａｐａｋ Ｃ１８柱预处理后,切换到Ｉｒｒｅｇｕｌａｒ＿ＨＣ１８分析柱,以甲醇－磷权二氢钾缓冲溶液（ＰＨ２．２）－０．０５ｍｏｌ／Ｌ四丁基溴化铵（３０：７０：４）为分析流动相进行分离测定,紫外线皮长为２９４ｎｍ。结果：左旋氧氟     

双氯芬酸钠微乳的家兔体内药代动力学考察

目的 :考察双氯芬酸钠微乳在家兔体内的药代动力学过程。方法 :家兔单次口服双氯芬酸钠微乳和双氯芬酸钠混悬液后 ,用 HPL C法测定血中双氯芬酸钠浓度。 结果 :双氯芬酸钠微乳和混悬液的 AU C0 -∞ 分别为 13.45 6和 10 .5 84μg· h· m l- 1 ,cmax 1 为 2 .85 2和 3.145 μg/m l,tmax1 为 1.438和 0 .75 0 h。 结论 :双氯芬酸钠微乳在家兔体内吸收过程较为平缓 ,可在较长时间内维持一定的血药浓度。     

猪血小板衍化生长因子的提取和纯化

目的 建立一种简单、经济的血小板衍化生长因子（PDGF）的纯化方法。方法 血小板衍化生长因子（PDGF）具有耐酸性（pH2.5）,耐热（100℃）以及耐受2%SDS的特性。采用酸醇提取、热处理、离子交换层析、分子筛等蛋白分离和纯化技术从猪血小板中提取和纯化PDGF。结果 猪血小板衍化生长因子（pPDGF）纯化倍数达7582倍,活性回收率为3%。结论 本方法简单、经济,纯化的猪血小板衍化生长因子(pPDGF）具有明显的生物学活性。     

Effect of regular training on the anthropometric parameters and urine steroids in childhood

The changes in the anthropometric data and urine steroid metabolites caused by regular training in children in two age groups (11 and 14 years old) were investigated. The skinfolds of older girls participating in regular athletic, swimming or soccer training were thinner compared with age-matched control groups (P < 0.01) and their body mass and constitution were lower (P < 0.05). In the other groups no significant differences were observable in the anthropometric parameters. The trained children in all groups had significantly higher exercise times on the cycle ergometer (P < 0.01, in young boysP < 0.05). The strength of their hands was lower in three trained groups: in younger boys (P < 0.05), in younger girls (P < 0.01) and in older girls (right handP < 0.01, left handP < 0.05). The urinary excretion of androsterone (P < 0.02), 11-ketopregnanetriol (P < 0.01) and pregnenetriol (P < 0.02) was decreased in the older trained girls; pregnenetriol was increased in younger boys (P < 0.05). Urinary excretion of cortisol metabolites was increased in trained boys [in younger boys: tetrahydrocorticosterone (P < 0.05) and 20-hydroxycortisol (P < 0.05); in older boys allotetrahydrocortisol (P < 0.02), cortisol (P < 0.05) and 20-hydroxycortisol (P < 0.05)]. There were no significant differences in the younger girls. In the trained older girls urinary excretion of cortisol metabolites was decreased: tetrahydrocortisone (P < 0.02), allotetrahydrocorticosterone (P < 0.01), tetrahydrocortisol (P < 0.05), -cortolone (P < 0.01), cortisol (P < 0.02), 6-hydroxycortisol (P < 0.01) and 20-hydroxycortisol (P < 0.05). A multivariate analysis of the data from the trained groups and sedentary, age-matched control groups showed that regular training has a significant effect on steroid excretion.     

Analytical Chiral Separation of the Stereoisomers of a Novel Carbonic Anhydrase Inhibitor and Its Deethylated Metabolite,and the Assignment of Absolute Configuration of the Human Metabolite and Chiral Degradation Products

Several approaches to the separation of four stereoisomers, 1–4, of a novel, topically active, carbonic anhydrase inhibitor, 1, with two chiral centers in the molecule and four isomers, 5–8, of its chiral metabolite, 5, were evaluated. These methods include nonchiral derivatization followed by separation on chiral stationary phases (CSPs) and chiral derivatization and separation on nonchiral columns and on CSPs. Baseline separation of stereoisomers 1–4 was achieved in less than 15 min after chiral derivatization with (S)-(+)-l-(l-naphthyl)ethyl isocyanate (NEIC) and chiral chromatography on a (R)-N-(3,5-dinitrobenzoyl)phenyl glycine (DNBPG) column under normal phase (NP) conditions. Similarly, isomers 5-8 were baseline separated in less than 20 min after derivatization with NEIC and chromatography on nonchiral (nitrophenyl) and chiral [(S)-(3,5-dinitrobenzoyl)leucine; DNBL] columns in series under the same NP chromatographic conditions. Only partial separation of the diastereomeric derivatives was observed on a variety of nonchiral columns. In addition, all other direct and indirect chiral separation approaches gave only partial separation of at least two stereoisomers within the group of 1–4 or 5–8. The details of chiral separations using various methods and separation () and capacity factors (k) of the derivatized isomers 1–8 on a series of chiral and nonchiral columns are presented. Using these methods, the absolute configuration of the human metabolite of 1 was established as S ₁ S ₂ (5), and the heat (HD) and light (LD) degradation products of 1 as R ₁ S ₂ (3) and S₁ S ₂ (5), respectively.     

The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil,and tamoxifen in metastatic breast-cancer patients

A high-pressure liquid chromatographic method for determination of the bisdioxopiperazine derivative ADR-529 (ICRF-187), a compound proven effective in protection against anthracycline-induced cardiotoxicity, has been developed. The limit of quantitation was 5 ng/ml using a narrow-bore 5-m silica column and UV detection. The method was used for determination of pharmacokinetic profiles of ADR-529 after a 3-weekly i.v. administration of different doses of ADR-529 (600–1000 mg/m²) together with different doses of epirubicin (E, 60–100 mg/m²), fixed-dose cyclophosphamide (C, 600 mg/m²), fixed-dose 5-fluorouracil (F, 600 mg/m²), and daily administration of tamoxifen (T, 30 mg; CEF-T) in the treatment of patients with metastatic breast cancer. Pharmacokinetic parameters for epirubicin were also determined. The aim of the study was to determine (1) whether the pharmacokinetics of ADR-529 as part of a combination with CEF-T changes with increasing doses of ADR-529 and increasing doses of epirubicin and (2) whether the pharmacokinetics of epirubicin in the same combinations is altered with the administration of increasing doses of ADR-529. A total of 82 patients were included. A crossover study including 16 of the patients showed no significant difference in epirubicin pharmacokinetic parameters when epirubicin was given with or without concomitant administration of ADR-529. Apart from minor changes in the distributional half-lives, the pharmacokinetic parameters of epirubicin were not altered with increasing doses of ADR-529, nor were the pharmacokinetic parameters of ADR-529 itself. Escalating doses of epirubicin did not significantly alter the pharmacokinetic parameters of ADR-529 with the exception of a 30% increase in the terminal half-life and a decrease in total body clearance when the epirubicin dose was raised from 60 to 100 mg/m². We conclude that concomitant administration of ADR-529 does not alter the distribution and elimination of epirubicin in doses suitable for preventing the anthracycline-induced cardiotoxicity.